Three important updates to the ADA “Living” Standard to know about are the incorporation of:
- International consensus report on continuous glucose monitoring and time in range (which tells a much more thorough story than A1c) (Standards 6 and 7)
- Results of Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial which reveals reduction in cardiovascular events with dulaglutide in adults with type 2 diabetes with or without existing cardiovascular disease (now that is exciting!!!) (Standards 9 and 10)
- FDA’a approval of liraglutide in pediatric patients with type 2 diabetes, and publication detailing drug’s effects in this population (a game changer as we now have more metformin as non-insulin options in pediatrics) (Standards 9 and 13)
Boy, such exciting updates! To review the updated standards for more details, please click below.
Please share your thoughts and subscribe to receive my blogs.
#ADA #updates #CGM #dulaglutide #pediatrics #liraglutide
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.